BofA Names ASML Top Semiconductor Equipment Pick on Growth, Valuation 
U.S. Probes Apex Logistics Over Nvidia AI Chip Shipments to China 
Meta, U.S. States Discuss Settlement in Teen Addiction Trial 
Salesforce Shares Surge as AI Demand Powers Q2 Earnings Beat 
Nvidia Pauses AI Cloud Financing Deals Amid Antitrust Concerns 
HP Stock Drops 9% Despite Q3 Earnings Beat and Raised 2026 Outlook 
Nvidia Reportedly Eyes $13 Billion Hugging Face Acquisition 
Honda, Nissan Eye Shared Vehicle Software Platform by 2029 
SoftBank Eyes $20 Billion Bond Sale to Refinance OpenAI Loan 
Adidas, Puma Shares Fall as Dick’s Sporting Goods Cuts Outlook 
OpenAI Data Center Chief Chris Malone Exits Ahead of Planned 2027 Listing 
Nvidia Revenue Soars 106% as AI Demand Hits ‘Inflection Point’ 
Mercer International Stock Surges 45% on C$20 Million Canada Funding 
PayPal Shares Sink as $50 Billion Takeover Bid Collapses 
Google Expands Gemini Enterprise With AI Tools for Legal Sector 
Trian Drops Wendy’s Take-Private Bid Plans, Shares Plunge 14% 
Yindjibarndi Appeals Fortescue Mining Compensation Ruling 
Add as a preferred source on Google
St. Louis, April 13, 2018 -- Express Scripts Holding Company (Nasdaq: ESRX) (“Express Scripts”) announced today its intention to release its 2018 first quarter financial results on Wednesday, May 2, 2018, after the market closes. Management will not be holding a conference call to review results.
A copy of the earnings release will be available at the Investor Information section of Express Scripts’ web site at http://www.express-scripts.com/corporate.
About Express Scripts
Express Scripts puts medicine within reach by practicing pharmacy smarter – taking bold action, delivering specialized care, creating innovative solutions and leveraging data insights - to make better health more affordable and accessible.
Headquartered in St. Louis, Express Scripts provides integrated pharmacy benefit management services, including network-pharmacy claims processing, home delivery pharmacy care, specialty pharmacy care, benefit-design consultation, drug utilization review, formulary management and medical and drug data analysis services. Express Scripts also distributes a full range of biopharmaceutical products and provides extensive cost-management and patient-care services.
For more information, visit Lab.Express-Scripts.com or follow @ExpressScripts on Twitter.
Contact: Jim Havel, Chief Financial Officer Ben Bier, Vice President Investor Relations (314) 810-3115 [email protected]
